A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.

@article{Bernard2013AME,
  title={A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom.},
  author={Lisa M. Bernard and David C. Mendelssohn and E. Dunn and C. A. Hutchison and Daniel T. Grima},
  journal={Journal of medical economics},
  year={2013},
  volume={16 1},
  pages={1-9}
}
OBJECTIVE There is limited information regarding the cost-effectiveness of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis in the UK. Using a UK National Health Service (NHS) perspective and final results of the Dialysis Clinical Outcomes Revisited (DCOR) study, an evaluation was performed to determine the cost-effectiveness of sevelamer compared to calcium-based phosphate binders for the first-line treatment of hyperphosphatemia in CKD… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research • 2015
View 3 Excerpts

Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients

International journal of nephrology and renovascular disease • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…